Table 52Tumor response outcomes—epoetin or darbepoetin versus control

Study IDDrugOutcome ReportedResponse DefinitionIntervention (Events/Total)Control (Events/Total)RR (95% CI) Calculateda
Engert 200995Epoetincomplete responseCR/CRu619/648614/6550.98 (0.96 to 1.01)
Engert 200995Epoetinpartial responseNR10/64811/6551.09 (0.47 to 2.54)
Goss 2005100Epoetinoverall response 6 wks post chemoCR+PR48/5242/520.88 (0.75 to 1.02)
Gupta 2009103Epoetinoverall response rate at 1 monthNR56/5853/570.96 (0.88 to 1.05)
Hoskin 200981Epoetintumor responseCR+PR149/151148/1491.01 (0.98 to 1.03)
Milroy 2011109Epoetintumor responseNR45/16048/1670.98 (0.69 to 1.38)
Pronzato 2010115Epoetintumor responseNR65/10756/1091.18 (0.93 to 1.50)
Wagner 200480Epoetintumor responseCR+PR12/1712/180.94 (0.60 to 1.48)
Untch 2011131 201137Darbepoetinpathological complete responsew w/o noninvasive residual57/35660/3771.01 (0.72 to 1.40)

CR = complete response; Cru = unconfirmed complete response; NR = not reported; PR = partial response

a

From event rates in tables.

From: Results

Cover of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update [Internet].
Comparative Effectiveness Reviews, No. 113.
Grant MD, Piper M, Bohlius J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.